North American Morning Briefing: Tech in Focus on -2- morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial of.
Vaxxinity s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
By Daniella Parra Vaxxinity, Inc. (Nasdaq: VAXX) said it demonstrated that VXX-401 lowers LDL cholesterol, supporting its potential for treating hypercholesterolemia. The VXX-401, a synthetic peptide vaccine, aims to provide a safe and effective solution against heart disease by targeting PCSK9, the company said in a statement. The studies were published in the Journal of […]
Vaxxinity, Inc. (NASDAQ:VAXX – Get Free Report)’s stock price fell 2.2% on Wednesday . The stock traded as low as $0.70 and last traded at $0.70. 463,479 shares changed hands during trading, an increase of 162% from the average session volume of 176,564 shares. The stock had previously closed at $0.72. Vaxxinity Price Performance The […]